Author

Topic: Molnupiravir experimental/carcinogenic and mutagenic risk drug !BEWARE! COVID19 (Read 39 times)

legendary
Activity: 3766
Merit: 1368
From the abstract:
...

Many mutagens damage DNA in dividing or resting cells [13]; in contrast, the mutagenic activity of rNHC in vivo would be limited to dividing cells where the synthesis of DNA precursors is ongoing, conditions analogous to the cell culture assay used here. Thus, an assessment of mutagenic potential to the host in vivo should focus on tissues rich in dividing cells and use sufficiently sensitive assays to detect single nucleotide substitutions.

rNHC has powerful in vitro and in vivo activity against a large number of highly pathogenic emerging RNA viruses and represents a potentially important drug for use in the current and future pandemics. However, the risks for the host may not be zero and these risks need to be carefully evaluated in undertaking therapies that are by their nature designed to change the coding capacity of a virus’ genetic material. Evaluating the utility of this drug should be done in those likely to receive the greatest benefit with monitoring provided to assess potential long-term genotoxic side effects. In addition, developing strategies to limit the potential for genotoxicity should be an important goal.
Supplementar

...

The point being that one has to find the "... dividing cells where the synthesis of DNA precursors is ongoing ..." in the host. What are we going to do to find the areas that are dividing? Cut up the host? Guess?

Nice drug, but, natural systems of nutrition and supplementation already have all this covered. Of course, the coverage isn't as direct as finding the the spots, and treating each of them in a timely manner.

No money in natural stuff.

Cool
hero member
Activity: 630
Merit: 506

  Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.

Merck Announces Supply Agreement with U.S. Government.

Will its trial data be as wrong as remdesivir and bamlanivimab were?


Linked below is a discussion of the mutagenic risk of Molnupiravir in an in vitro study.

https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab247/6272009
Jump to: